Arkolith/Insider Trading/SAGE/Form 4

Benecchi Christopher

Chief Business OfficerSage Therapeutics, Inc. (SAGE) · full profile →Form 4 · filed Aug 7, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 5, 2024Tax withholding(F)5K$8.96$43K18K
Aug 5, 2024Grant(A)16K—$023K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-006086) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML